- Home
- FCO vs IGMS Comparison
FCO vs IGMS Comparison
Compare FCO & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- IGMS
- Stock Information
- Founded
- FCO 1991
- IGMS 1993
- Country
- FCO United Kingdom
- IGMS United States
- Employees
- FCO N/A
- IGMS N/A
- Industry
- FCO Investment Managers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- IGMS Health Care
- Exchange
- FCO Nasdaq
- IGMS Nasdaq
- Market Cap
- FCO 78.3M
- IGMS 82.1M
- IPO Year
- FCO N/A
- IGMS 2019
- Fundamental
- Price
- FCO $6.11
- IGMS $1.14
- Analyst Decision
- FCO
- IGMS Hold
- Analyst Count
- FCO 0
- IGMS 8
- Target Price
- FCO N/A
- IGMS $6.14
- AVG Volume (30 Days)
- FCO 100.1K
- IGMS 155.8K
- Earning Date
- FCO 01-01-0001
- IGMS 05-20-2025
- Dividend Yield
- FCO 14.96%
- IGMS N/A
- EPS Growth
- FCO N/A
- IGMS N/A
- EPS
- FCO 0.43
- IGMS N/A
- Revenue
- FCO N/A
- IGMS $2,679,000.00
- Revenue This Year
- FCO N/A
- IGMS $121.76
- Revenue Next Year
- FCO N/A
- IGMS $46.83
- P/E Ratio
- FCO $12.30
- IGMS N/A
- Revenue Growth
- FCO N/A
- IGMS 25.77
- 52 Week Low
- FCO $4.73
- IGMS $0.92
- 52 Week High
- FCO $6.63
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- FCO 62.53
- IGMS 44.45
- Support Level
- FCO $5.96
- IGMS $1.11
- Resistance Level
- FCO $6.25
- IGMS $1.22
- Average True Range (ATR)
- FCO 0.13
- IGMS 0.11
- MACD
- FCO 0.04
- IGMS -0.01
- Stochastic Oscillator
- FCO 78.57
- IGMS 22.22
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.